人民财讯12月22日电，《泉州市现代体育产品先进制造业集群培育提升三年行动方案(2025—2027年)》 印发。其中提到，拓展运动装备全场景生态圈。鼓励企业顺应健身场景泛化、运动装备细分化等消费新 需求，加大个性化、定制化、智能化研发投入，拓展智能可穿戴、功能性鞋服、康复装备等新赛道。充 分发挥"链主"企业作用，瞄准运动健身器材、户外运动装备、轻型冰雪装备等热点领域开展延链补链， 引育体育运动装备、运动健康食品、智能穿戴等企业，构建覆盖居家健身、专业训练及休闲户外的"吃 穿用练"全场景、"从头到脚"全品类运动装备生态圈。 ...

Group 1 - Xiangyu Medical has been focusing on the rehabilitation market for over 20 years, developing clinical rehabilitation equipment and integrated solutions based on specific clinical needs [1] - The company plans to launch more products and solutions in rehabilitation robotics, brain-computer interfaces, AI healthcare, mental health, and cardiopulmonary rehabilitation [1] Group 2 - Hualan Biological is evaluating various production expression systems for recombinant human albumin, including yeast, plant cell, and bacterial expression systems [2] - Currently, no domestic companies have obtained drug registration certificates for recombinant human albumin, which could alleviate the high reliance on imports if approved [2] Group 3 - Sanxin Medical identifies the ASEAN market as one of the most promising growth markets for blood dialysis globally, with significant sales achievements in countries like Indonesia, Malaysia, Thailand, and Vietnam [3] - The company aims to leverage multilateral economic cooperation mechanisms between China and ASEAN countries for further overseas market expansion [3] Group 4 - Renhe Pharmaceutical's outsourcing production aims to enrich the variety of products on the market, focusing on complementary products that the company does not have registration for or lacks production capacity [4] - All revenue and profits from outsourced products are reflected in the company's financial statements [4] Group 5 - Jinbo Biological has established partnerships with L'Oréal Group for raw material products, generating certain revenue [5] - The company is prioritizing market expansion in Southeast Asia while focusing on the speed of registration for medical devices [5] Group 6 - Guilin Sanjin's "Dizziness Ning" series sales surpassed 100 million yuan in 2021, with a target for double-digit growth this year [6] - The company is supporting second and third-tier products, which are showing better growth trends compared to first-tier products [6]